SI-BONE (NASDAQ:SIBN) Price Target Raised to $18.00 at Truist Financial

SI-BONE (NASDAQ:SIBN) had its target price upped by Truist Financial from $16.00 to $18.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on SIBN. Morgan Stanley reduced their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a report on Wednesday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $23.00.

SI-BONE Stock Up 3.9 %

Shares of SIBN opened at $12.92 on Wednesday. The business’s 50 day moving average is $14.03 and its 200 day moving average is $14.29. The company has a current ratio of 8.25, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22. SI-BONE has a 12-month low of $11.76 and a 12-month high of $21.70. The company has a market capitalization of $541.86 million, a PE ratio of -14.04 and a beta of 1.22.

Insider Activity at SI-BONE

In other news, insider Anthony J. Recupero sold 2,087 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $14.17, for a total transaction of $29,572.79. Following the sale, the insider now directly owns 236,717 shares in the company, valued at approximately $3,354,279.89. This represents a 0.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 7,147 shares of company stock valued at $102,194. 3.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On SI-BONE

Large investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after purchasing an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in SI-BONE in the second quarter worth $61,000. Walleye Capital LLC purchased a new position in SI-BONE during the third quarter worth $144,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in SI-BONE by 24.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after buying an additional 2,108 shares during the period. Finally, Arizona State Retirement System increased its position in SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after acquiring an additional 903 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.